These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28353185)

  • 41. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
    Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
    Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents.
    Chidambaran V; Venkatasubramanian R; Sadhasivam S; Esslinger H; Cox S; Diepstraten J; Fukuda T; Inge T; Knibbe CAJ; Vinks AA
    Paediatr Anaesth; 2015 Sep; 25(9):911-923. PubMed ID: 25975390
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.
    Zhao M; Lepak AJ; Andes DR
    Bioorg Med Chem; 2016 Dec; 24(24):6390-6400. PubMed ID: 27887963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
    Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
    J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints.
    Ambrose PG
    Treat Respir Med; 2005; 4 Suppl 1():5-11. PubMed ID: 15846151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis.
    Santos RP; Prestidge CB; Brown ME; Urbancyzk B; Murphey DK; Salvatore CM; Jafri HS; McCracken GH; Ahmad N; Sanchez PJ; Siegel JD
    Pediatr Pulmonol; 2009 Feb; 44(2):148-54. PubMed ID: 19137597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs.
    Mouton JW; Dudley MN; Cars O; Derendorf H; Drusano GL
    Int J Antimicrob Agents; 2002 Apr; 19(4):355-8. PubMed ID: 11978507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.
    Onufrak NJ; Forrest A; Gonzalez D
    Clin Ther; 2016 Sep; 38(9):1930-47. PubMed ID: 27449411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pharmacokinetic/pharmacodynamic analysis in microbiology: a tool for the evaluation of the antimicrobial treatment].
    Canut Blasco A; Aguilar Alfaro L; Cobo Reinoso J; Giménez Mestre MJ; Rodríguez-Gascón A
    Enferm Infecc Microbiol Clin; 2015 Jan; 33(1):48-57. PubMed ID: 23850188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).
    Zelenitsky SA; Rubinstein E; Ariano RE; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i67-72. PubMed ID: 23587780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
    Mouton JW; Dudley MN; Cars O; Derendorf H; Drusano GL
    J Antimicrob Chemother; 2005 May; 55(5):601-7. PubMed ID: 15772142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents - minimum inhibitory concentration versus time-kill curves.
    Schmidt S; Schuck E; Kumar V; Burkhardt O; Derendorf H
    Expert Opin Drug Discov; 2007 Jun; 2(6):849-60. PubMed ID: 23489002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
    Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
    J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
    Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interpreting culture and susceptibility data in critical care: perks and pitfalls.
    Boothe DM
    J Vet Emerg Crit Care (San Antonio); 2010 Feb; 20(1):110-31. PubMed ID: 20230440
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.
    Lyons MA; Lenaerts AJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients.
    Roberts JA; Kirkpatrick CM; Lipman J
    J Antimicrob Chemother; 2011 Feb; 66(2):227-31. PubMed ID: 21118912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.